Trial Profile
A Phase II, Single-center, Randomized Study of Vinorelbine Plus Apatinib Versus Vinorelbine as Second-Line or Third-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer (NAN Trail)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Vinorelbine
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms NAN Trail
- 08 Jun 2021 Primary endpoint (PFS) has been met, according to Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 08 Jun 2021 Status changed from recruiting to completed, according to Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology